Search results for: "Novo Nordisk"

(283 records)

Novo Nordisk enters collaboration with University of Oxford on type 2 diabetes

Novo Nordisk enters collaboration with University of Oxford on type 2 diabetes

The partnership will enable scientists from Novo Nordisk and University of Oxford to collaborate to discover innovative approaches for treating type 2 diabetes. As part of the...
Media
Pharma companies to grow overseas sales at CPhI South East Asia

Pharma companies to grow overseas sales at CPhI South East Asia

CPhI South East Asia returns for its sixth edition to the Jakarta International Expo, 22-24 March, as regional pharma companies expect robust growth

Fluor to design and build $2bn API production facility for Novo Nordisk

The global healthcare company will use the facility in North Carolina to produce active pharmaceutical ingredients for diabetes drugs

Type 2 diabetes mellitus market ripe with opportunities for potential investors, says GBI Research

The increasing demand for type 2 diabetes mellitus (T2DM) therapeutics, caused by rising prevalence of the disease, has resulted in a large and competitive market landscape....
Ingredients
Ablynx acheives first milestone as part of collaboration with Novo Nordisk

Ablynx acheives first milestone as part of collaboration with Novo Nordisk

Multi-specific nanobody candidate reaches discovery milestone
Media
Increased diagnoses of haemophilia A and B will drive Asia-Pacific market growth to 2022

Increased diagnoses of haemophilia A and B will drive Asia-Pacific market growth to 2022

The haemophilia A and B markets in the Asia-Pacific (APAC) region are forecast to expand from $444.9 million and $76.3 million in 2015 to $699.1 million and $112.9 million by...

Nordic Nanovector appoints Lisa Rojkjaer, MD as Chief Medical Officer

Nordic Nanovector ASA (OSE: NANO) is pleased to announce that Lisa Rojkjaer, MD has joined the company today as Chief Medical Officer (CMO) and as a member of the Executive...

Effect of insulin on cell growth and virus production

Improving influenza and adenovirus yield with the addition of insulin for vaccine production
Drug Delivery
High-purity quaternary ammonium compounds (Quats)

High-purity quaternary ammonium compounds (Quats)

Visit Novo Nordisk Pharmatech, booth 5B1 at CPHI Worldwide
Media
Newer therapies will steer type 2 diabetes market in South-East Asia to $2.7 billion by 2022

Newer therapies will steer type 2 diabetes market in South-East Asia to $2.7 billion by 2022

Increase will be driven by the growing use of recently approved and emerging branded T2DM therapeutics, in favor of lower-cost generic products, says report
Design & Build
Novo Nordisk to invest more than €100m in production plants in Chartres, France

Novo Nordisk to invest more than €100m in production plants in Chartres, France

Further strengthening Chartres’ position in the Danish firm's global product supply organisation

Ablynx to work with Novo Nordisk on nanobody drug discovery

Will receive a €5m upfront payment, research funding and potential future milestones and royalties on net sales
Manufacturing
Novo Nordisk to run all production plants on renewable power by 2020

Novo Nordisk to run all production plants on renewable power by 2020

Sets a target of zero carbon emissions from electricity at all global sites in five years

Novo Nordisk invests DKK2.1bn in new insulin filling facility in Denmark

The facility will produce medicines for the treatment of diabetes and obesity and 450 new jobs will be created

Novo Nordisk and University of Washington to explore brain's role in regulating blood sugar and obesity

And develop new treatments for diabetes and obesity

LIVE FROM CPHI: 2015 CPhI Pharma Awards winners announced

Seven prestigious and worthy winners chosen by the jury from more than 70 entries

Trending Articles

  1. Nicox’s NCX 470 new drug application submitted in the United States by Kowa The submission is based on positive results from two Phase III clinical trials (Mont Blanc and Denali)
  2. Thermo Fisher's Patheon becomes exclusive third-party CDMO for KinetiSol technology The agreement will install KinetiSol Formulator equipment across Patheon's Bend and Cincinnati OSD sites, offering pharma customers an integrated development-to-commercial pathway for poorly soluble drug candidates
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Annex 1 at the transfer point: how to meet the evolving evidence challenge As Annex 1 raises expectations for contamination control, transfer-point evidence must become more dynamic, connected and defensible throughout the entire product lifecycle
  4. Sanofi offers EU commitments for flu vaccine disparagement claims Sanofi has proposed remedies to EU antitrust regulators after allegations it disparaged rival CSL Seqirus's Fluad vaccine in Germany and France since 2024
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Back to basics: a simple guide to checkweighing in pharmaceutical production Mettler-Toledo’s Miriam Krechlok tells Dr Kevin Robinson how checkweighing helps pharmaceutical manufacturers to verify product completeness, control fill levels and maintain compliance, safety and efficiency

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy See all

You may also like

Digital The AI-driven biotech and China Medical System have struck a second collaboration in three months, targeting a mass-market CNS indication via a novel mechanism identified by...
Insilico Medicine and CMS deepen AI drug discovery tie-up with new CNS collaboration

Insilico Medicine and CMS deepen AI drug discovery tie-up with new CNS collaboration

Read more
Research & Development The global study builds on US POINTER trial findings, testing whether adding a metabolism-targeting drug to structured lifestyle programmes can further reduce cognitive decline...
Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline

Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline

Read more
Manufacturing Piramal Pharma Limited (PPL) (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a...
Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones

Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones

Read more
Manufacturing The FDA's pre-licence inspection approval of WuXi Biologics' MFG8 facility will strengthen the CRDMO's commercial manufacturing network, supporting the global supply of a...
WuXi Biologics' Hebei facility secures FDA PLI approval for commercial autoimmune biologics manufacturing

WuXi Biologics' Hebei facility secures FDA PLI approval for commercial autoimmune biologics manufacturing

Read more
Manufacturing Boehringer Ingelheim has selected the osapiens HUB for Mobile Maintenance for its global, regulated manufacturing operations
Boehringer Ingelheim standardises plant maintenance globally with osapiens

Boehringer Ingelheim standardises plant maintenance globally with osapiens

Read more
Manufacturing With throughput up to 100 kg/h, the new twin-screw extruder brings lab-grade process understanding into pilot-scale production, enabling users to validate process parameters...
Brabender TwinLab B-TSE-S 30/40: Pilot-scale extrusion with lab-level insight

Brabender TwinLab B-TSE-S 30/40: Pilot-scale extrusion with lab-level insight

Read more
Dosage Forms While injection pens and weight-loss pills are gaining ground across the Western world, the debate focuses one-sidedly on the kilos and not on the body’s health and the...
Obesity medication: fast results … but at the expense of long-term health

Obesity medication: fast results … but at the expense of long-term health

Read more
Pharmaceutical The agreement will expand Teva’s biosimilars pipeline, with the company securing exclusive commercialisation rights for Polpharma Biologics’ proposed ocrelizumab biosimilar...
Teva and Polpharma Biologics sign global licensing deal for Ocrevus biosimilar candidate

Teva and Polpharma Biologics sign global licensing deal for Ocrevus biosimilar candidate

Read more